Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6518201 | 1.00 | KMT2A (0.47) | KMT2AMEN1LMNAADORA3P2RX7 | |
| SCHEMBL6518195 | 1.00 | KMT2A (0.47) | KMT2AMEN1LMNAADORA3P2RX7 | |
| SCHEMBL16323142 | 0.88 | KMT2A (0.45) | KMT2AMEN1LMNAADORA3P2RX7 | |
| SCHEMBL1225559 | 0.86 | P2RX7 (0.50) | KMT2AMEN1P2RX7ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL1225887 | 0.85 | P2RX7 (0.49) | KMT2AMEN1P2RX7ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL1225886 | 0.85 | P2RX7 (0.49) | KMT2AMEN1P2RX7ALDH1A1TDP1 | |
| SCHEMBL6519200 | 0.84 | TDP1 (0.49) | KMT2AMEN1LMNAP2RX7ALDH1A1 | |
| SCHEMBL6519197 | 0.84 | TDP1 (0.49) | KMT2AMEN1LMNAP2RX7ALDH1A1 | |
| SCHEMBL7661275 | 0.80 | ADRA1A (0.48) | KMT2AMEN1P2RX7TSHR | |
| SCHEMBL1225883 | 0.73 | P2RX7 (0.49) | P2RX7TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | claimed |
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX7, P2RX3 | KMT2A 3668/4885MEN1 2873/4885LMNA 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.